Featuring an interview with Dr Erika Hamilton, including the following topics:

• General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
• Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11)
• Mechanisms of resistance to endocrine therapy (10:08)
• Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26)
• Other applications for PROTACs (24:24)
• Emerging data from the Phase III evERA trial (27:38)
• Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51)

CME information and select publications